Search

JP-7857371-B2 - Monascus red fungus, compositions for the prevention or treatment of non-alcoholic fatty liver disease, and uses of the same Monascus red fungus

JP7857371B2JP 7857371 B2JP7857371 B2JP 7857371B2JP-7857371-B2

Inventors

  • 李俊霖
  • 潘子明
  • 潘佳岳
  • 許雅▲うぇん▼

Assignees

  • 晨暉生物科技股▲分▼有限公司

Dates

Publication Date
20260512
Application Date
20241004
Priority Date
20240607

Claims (20)

  1. This is a type of Monascus pilosus (Aspergillus pylosus) characterized by being deposited with the National Industrial, Food and Marine Bacteria Collections Ltd. (NCIMB Ltd.) in the United Kingdom under accession number NCIMB 44103.
  2. Use of Monascus pilosus, characterized by being deposited with the National Industrial, Food and Marine Bacteria Collections Ltd. (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44103, in the manufacture of compositions for the prevention or treatment of non-alcoholic fatty liver disease.
  3. A composition for use in the prevention or treatment of non-alcoholic fatty liver disease, characterized in that it contains an effective amount of a functional component, the functional component being extracted from a red yeast rice ferment product that can be produced by fermenting a substrate using Monascus poultry, and the Monascus poultry being Monascus poultry deposited with the National Industrial, Food and Marine Bacteria Collection Ltd (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44103.
  4. The composition according to claim 3, characterized in that the non-alcoholic fatty liver is caused by at least one condition selected from the group consisting of obesity, hypertension, hyperlipidemia, and diabetes.
  5. The composition according to claim 3, characterized in that it reduces serum liver function markers AST and ALT.
  6. The composition according to claim 3, characterized in that it suppresses the accumulation of fat in liver tissue.
  7. The composition according to claim 3, characterized in that it reduces the content of total cholesterol (TC) and triglycerides (TG) in the liver.
  8. The composition according to claim 3, characterized in that it improves lipid droplet accumulation and fat infiltration in the liver.
  9. The composition according to claim 3, characterized in that it has the function of improving the richness of beneficial intestinal bacteria and the function of altering the composition of intestinal bacteria.
  10. The composition according to claim 3, characterized in that the functional component comprises at least one selected from the group consisting of monascinol, ankaflavin, and monascin.
  11. The composition according to claim 3, characterized in that the substrate is a mixture of rice, yam, or related carbohydrates.
  12. The composition according to claim 3, characterized in that the effective amount is such that an adult ingests at least 1.5 milligrams to 12 milligrams of the functional ingredient daily when used alone.
  13. A composition for use in the prevention or treatment of non-alcoholic fatty liver disease, characterized in that it contains an effective amount of red yeast rice ferment, the red yeast rice ferment can be produced by fermenting a substrate using Monascus pylori, and the Monascus pylori is Monascus pylori deposited with the National Industrial, Food and Marine Bacteria Collection Ltd (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44103.
  14. The composition according to claim 13, characterized in that the non-alcoholic fatty liver is caused by at least one condition selected from the group consisting of obesity, hypertension, hyperlipidemia, and diabetes.
  15. The composition according to claim 13, characterized in that it reduces serum liver function markers AST and ALT.
  16. The composition according to claim 13, characterized in that it suppresses the accumulation of fat in liver tissue.
  17. The composition according to claim 13, characterized in that it reduces the content of total cholesterol (TC) and triglycerides (TG) in the liver.
  18. The composition according to claim 13, characterized in that it improves lipid droplet accumulation and fat infiltration in the liver.
  19. The composition according to claim 13, characterized in that it has the function of improving the richness of beneficial intestinal bacteria and the function of altering the composition of intestinal bacteria.
  20. The composition according to claim 13, characterized in that the substrate is a mixture of rice, yam, or related carbohydrates.

Description

NCIMB NCIMB 44103 This invention relates to the technical field of preventing or treating non-alcoholic fatty liver disease, and more particularly to the technical field of compositions for preventing or treating non-alcoholic fatty liver disease that contain Monascus red yeast rice, its fermented products, or functional components such as the fermented products. Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in Western countries. While it accounts for approximately 20% to 30% of the general adult population, the prevalence in obese and diabetic patients reaches 70% to 90%. According to a survey by a domestic research institution, the prevalence of NAFLD is approximately 11.5%. In recent years, insulin resistance has been recognized as a significant cause of NAFLD, and therefore, patients with NAFLD have a clear association with metabolic syndromes. Increasing evidence is showing a link between NAFLD and an increased risk of developing cardiovascular disease, and this risk increases with the severity of NAFLD. Non-alcoholic fatty liver disease (NAF) refers to fatty liver disease in which excessive fat accumulates in liver cells, and is not caused by alcohol. Generally speaking, it is normal for the liver to contain some fat, however, if 5% to 10% or more of the liver's weight is fat, it is called fatty liver disease. NAF often occurs in overweight, obese, or those with diabetes, high cholesterol, or high triglycerides. Rapid dieting and an unbalanced diet can also lead to NAF. The harm that NAF poses to the body cannot be ignored. Over time, fatty liver can lead to cirrhosis, and in severe cases, liver cancer or liver failure. NAF can directly lead to decompensated cirrhosis, hepatocellular carcinoma, and recurrence of transplanted livers, as well as influencing the progression of other chronic liver diseases and contributing to the development of type 2 diabetes and atherosclerosis. Non-alcoholic fatty liver disease (NDL) can cause liver damage similar to that of alcoholism, and in the most serious cases, it can progress to cirrhosis or liver failure. The gut microbiota refers to the vast number of bacteria that inhabit the human digestive tract. Its influence on various physiological and pathological phenomena in the human body is quite clear and important. The interaction between fatty liver and the gut microbiota is closely related, and this relationship is called the gut-liver axis. The composition and metabolites of the gut microbiota affect hepatic lipid metabolism, inflammatory responses, and the degree of fibrosis. Several studies have found that patients with non-alcoholic fatty liver disease (NALF) exhibit reduced diversity in their gut microbiota, making them more susceptible to dysbiosis. Furthermore, abnormal gut microbiota produce harmful substances such as phenylacetic acid, which enter the liver via the hepatic portal vein, promoting the formation and progression of fatty liver. Therefore, regulating the gut microbiota ecosystem, for example by increasing the intake of beneficial bacteria, can be helpful in improving fatty liver. This figure shows the species identification and recognition process for Aspergillus oryzae according to the present invention.This is a phylogenetic tree showing the relationships between the β-tubulin sequences of Aspergillus oryzae (red yeast rice) species after alignment.This is a phylogenetic tree showing the relationships between the Aspergillus oryzae species after alignment of their ITS sequences.This shows the results of PCR analysis demonstrating the species specificity of the Aspergillus oryzae according to the present invention.This shows the results of PCR analysis of the pksCT gene of Aspergillus oryzae according to the present invention.This is a photograph showing the ascocarp morphology of the Aspergillus oryzae of the present invention.These are liver pathology tissue section images showing the long-term effects of the red yeast rice and its monascinol in mice on a high-fat diet according to the present invention.This figure shows the relative richness of the top 10 ranked intestinal flora groups, as determined by high-throughput sequencing, regarding the long-term effects of the red yeast rice and its monascinol on the intestinal flora of mice fed a high-fat diet according to the present invention.This figure shows a comparison of the richness of bacterial communities between each test group (L008, H008, and Msol groups) and the HFD group.This figure shows the partial least squares discriminant analysis (PLS-DA) of the β-diversity of the enterobacteria in each test group (ND, HFD, L008, H008, and Msol groups). Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention pertains. The details of the present invention will be explicitly described below using examples, but these